Explore

Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs

AN2 Therapeutics Reports Q1 2026 Financial Results and Advances Clinical Programs
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Trendline Trendline
BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates

BridgeBio's Attruby Shows Potential Superiority Over Pfizer's Tafamidis in ATTR-CM Survival Rates
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 2026 Financial Results and Pipeline Progress

Enanta Pharmaceuticals Reports Q2 2026 Financial Results and Pipeline Progress

Enanta Pharmaceuticals Reports Q2 2026 Financial Results and Pipeline Progress
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials

Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials

Curis Reports Q1 2026 Financial Results and Advances Cancer Drug Trials
Trendline Trendline
Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus

Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus

Savara Inc. to Participate in BioConnect Investor Conference, Highlighting Rare Respiratory Disease Focus
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas